Biocon on 10 August 2013 announced that it has launched its first biologic drug ALZUMAb for Psoriasis. The newly launched drug will be sold in the market at about half the price of the similar drugs of multi-national companies available in the market. A vial of the drug from Biocon will be available in India at 7950 rupees.
As per the announcement made by Kiran Mazumdar-Shaw, the Chairman and Managing Director of Biocon this is the world’s first novel anti-CD6 antibody to treat psoriasis.
The drug ALZUMAb has been made using cells and doesn't include artificial chemicals. It took about 10 years for Biocon to develop the drug.
Psoriasis is immune-mediated disease that effects the skin. the Disease on an average affects about 10-20 million Indians and it attacks the immune system of human beings. In generally occurs, when the immune system mistakes a normal skin cell for a pathogen, and sends out faulty signals that cause overproduction of new skin cells.
Biocon is an India biotech company and is focused on delivering affordable innovation. It is committed to reduce therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases by leveraging India's cost advantage to deliver affordable healthcare solutions to patients, partners and healthcare systems across the globe.
Some of its key innovations includes
• World's first Pichia based recombinant human Insulin, Insugen
• Insulin analogue Glargine, BASALOG
• India's first indigenously produced monoclonal antibody BioMAb-EGFR, for head & neck cancer.
When: 10 August 2013
DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.